Avantor (NYSE:AVTR - Get Free Report) was upgraded by investment analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a note issued to investors on Sunday, Wall Street Zen reports.
Other analysts also recently issued reports about the company. Morgan Stanley upped their price objective on Avantor from $10.00 to $14.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 30th. Deutsche Bank Aktiengesellschaft reissued a "hold" rating and set a $13.00 target price on shares of Avantor in a research note on Thursday, July 30th. Royal Bank Of Canada lifted their price target on shares of Avantor from $9.00 to $14.00 and gave the company a "sector perform" rating in a report on Thursday, July 30th. Citigroup increased their price objective on shares of Avantor from $9.00 to $11.00 and gave the company a "neutral" rating in a research note on Wednesday, July 8th. Finally, Stifel Nicolaus boosted their target price on shares of Avantor from $8.00 to $15.00 and gave the stock a "hold" rating in a research note on Thursday, July 30th. Two analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus price target of $12.88.
Read Our Latest Research Report on AVTR
Avantor Stock Up 1.9%
NYSE:AVTR opened at $15.69 on Friday. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.18 and a current ratio of 1.78. The company has a market cap of $10.61 billion, a price-to-earnings ratio of -18.68, a P/E/G ratio of 11.83 and a beta of 0.94. The stock's fifty day moving average price is $14.67 and its two-hundred day moving average price is $11.11. Avantor has a 52-week low of $7.26 and a 52-week high of $16.38.
Avantor (NYSE:AVTR - Get Free Report) last announced its quarterly earnings data on Wednesday, July 29th. The company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.19 by $0.02. The business had revenue of $1.69 billion during the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a negative net margin of 8.81% and a positive return on equity of 9.92%. The company's revenue was up .5% on a year-over-year basis. During the same period in the previous year, the business earned $0.24 earnings per share. Avantor has set its FY 2026 guidance at 0.800-0.830 EPS. On average, analysts anticipate that Avantor will post 0.81 EPS for the current year.
Institutional Investors Weigh In On Avantor
Hedge funds have recently added to or reduced their stakes in the business. SJS Investment Consulting Inc. increased its position in Avantor by 1,599.7% in the 1st quarter. SJS Investment Consulting Inc. now owns 5,235 shares of the company's stock valued at $41,000 after acquiring an additional 4,927 shares during the period. Elevation Wealth Partners LLC grew its stake in shares of Avantor by 72.3% in the third quarter. Elevation Wealth Partners LLC now owns 2,803 shares of the company's stock worth $42,000 after purchasing an additional 1,176 shares during the last quarter. IFP Advisors Inc grew its stake in shares of Avantor by 901.4% in the second quarter. IFP Advisors Inc now owns 5,858 shares of the company's stock worth $58,000 after purchasing an additional 5,273 shares during the last quarter. Parallel Advisors LLC increased its holdings in Avantor by 21.4% in the first quarter. Parallel Advisors LLC now owns 8,452 shares of the company's stock valued at $66,000 after purchasing an additional 1,491 shares during the period. Finally, State of Wyoming acquired a new stake in Avantor in the second quarter valued at $74,000. 95.08% of the stock is currently owned by institutional investors and hedge funds.
About Avantor
(
Get Free Report)
Avantor, Inc is a global provider of products, services and solutions used in the life sciences and advanced technology industries. The company supplies materials and equipment that support research, drug discovery and development, biopharmaceutical manufacturing, clinical and diagnostic activities, and other laboratory applications.
Its offerings include laboratory chemicals and reagents, consumables, single-use manufacturing technologies, bioprocessing products, equipment, and related services.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Avantor, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Avantor wasn't on the list.
While Avantor currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.